Simona Blotta
Simona Blotta
Medical Doctor, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy
Email verificata su
Citata da
Citata da
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
P Tassone, P Tagliaferri, A Perricelli, S Blotta, B Quaresima, ML Martelli, ...
British journal of cancer 88 (8), 1285-1291, 2003
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
J Rosenblatt, B Vasir, L Uhl, S Blotta, C MacNamara, P Somaiya, Z Wu, ...
Blood, The Journal of the American Society of Hematology 117 (2), 393-402, 2011
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
J Jakubikova, S Adamia, M Kost-Alimova, S Klippel, D Cervi, JF Daley, ...
Blood, The Journal of the American Society of Hematology 117 (17), 4409-4419, 2011
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
S Blotta, J Jakubikova, T Calimeri, AM Roccaro, N Amodio, AK Azab, ...
Blood, The Journal of the American Society of Hematology 120 (25), 5002-5013, 2012
RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma
AK Azab, F Azab, S Blotta, CM Pitsillides, B Thompson, JM Runnels, ...
Blood, The Journal of the American Society of Hematology 114 (3), 619-629, 2009
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
MA Shammas, H Koley, RC Bertheau, P Neri, M Fulciniti, P Tassone, ...
Leukemia 22 (7), 1410-1418, 2008
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma
J Jakubikova, D Cervi, M Ooi, K Kim, S Nahar, S Klippel, D Cholujova, ...
Haematologica 96 (8), 1170, 2011
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance
S Blotta, P Tassone, RH Prabhala, P Tagliaferri, D Cervi, S Amin, ...
Blood, The Journal of the American Society of Hematology 114 (15), 3276-3284, 2009
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents
P Tassone, S Blotta, C Palmieri, S Masciari, B Quaresima, M Montagna, ...
International journal of oncology 26 (5), 1257-1263, 2005
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma
P Neri, P Tassone, M Shammas, H Yasui, E Schipani, RB Batchu, S Blotta, ...
Leukemia 21 (12), 2519-2526, 2007
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways
P Tagliaferri, P Tassone, S Blotta, C Viscomi, F Grillone, A Budillon, ...
Current Drug Targets 6 (3), 289-300, 2005
In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells
P Neri, H Yasui, T Hideshima, P Tassone, N Raje, CP Laurence, ...
British journal of haematology 134 (1), 37-44, 2006
Anti-DKK1 mAb (BHQ880) as a potential therapeutic for multiple myeloma.
M Fulciniti, P Tassone, T Hideshima, S Vallet, S Ettenberg, D Stover, ...
Blood, The Journal of the American Society of Hematology 110 (11), 551-551, 2007
A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.
G Gorgun, E Calabrese, M Mani, T Hideshima, H Ikeda, G Perrone, ...
Blood 112 (11), 1719, 2008
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
AM Roccaro, IM Ghobrial, S Blotta, SP Treon, M Malagola, KC Anderson, ...
Biologics: Targets and Therapy 2 (3), 419-431, 2008
Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial
G Martinelli, A Santoro, C Gambacorti-Passerini, SV Polo, SR Solomon, ...
J. Clin. Oncol 40 (7024), 10.1200, 2022
Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical …
J Jakubikova, DN Cervi, JF Daley, D Cholujova, MG Ooi, S Klippel, ...
Blood 114 (22), 954, 2009
TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.
R Prabhala, D Pelluru, P Neri, M Fulciniti, JJ Driscoll, S Weihua, S Blotta, ...
Blood, The Journal of the American Society of Hematology 110 (11), 3517-3517, 2007
The novel, orally available multi-kinase inhibitor BAY 73-4506 in multiple myeloma
I Breitkreutz, MS Raab, O Christensen, A Zimmerhackl, J Zhang, S Blotta, ...
Blood, The Journal of the American Society of Hematology 112 (11), 2766-2766, 2008
Waldenström macroglobulinemia: new therapeutic options
AM Roccaro, X Leleu, S Blotta, N Burwik, A Vacca, D Russo, IM Ghobrial
Cancer Therapy 6, 227-238, 2008
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20